Article-Journal

Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update
Systemic radioimmunotherapy (RIT) is arguably the most effective and least toxic anticancer treatment for non-Hodgkin lymphoma (NHL). …
May 1, 2023
Cite DOI
Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE
The aim of this paper was to investigate correlations between pre- therapeutic [68Ga]Ga-DOTA-TOC uptake and absorbed dose to tumours …
Feb 10, 2023
Cite DOI
Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis
Two ongoing phase I studies are investigating the use of radium-224 adsorbed to calcium carbonate micro particles (224Ra-CaCO3-MP) to …
Feb 8, 2023
Cite DOI
Scar imaging in the dyssynchronous left ventricle: Accuracy of myocardial metabolism by positron emission tomography and function by echocardiographic strain
Response to cardiac resynchronization therapy (CRT) is reduced in patients with high left ventricular (LV) scar burden, in particular …
Feb 1, 2023
Cite DOI
Imaging the tumour microenvironment in rectal cancer: Decline in tumour blood flow during radiotherapy predicts good outcome
Measuring rectal tumour response to radiation is pivotal to restaging patients and for possibly stratification to a watch-and-wait …
Jan 23, 2023
Cite DOI
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
MRI, applying dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) sequences, and 18F-fluorodeoxyglucose (18F-FDG) PET/CT …
Nov 1, 2022
Cite DOI
Correction to: Quantitative SPECT/CT imaging of lead-212: a phantom study
No abstract available
Oct 10, 2022
Cite DOI
Comparison of [18F]fluciclovine and [18F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
[18F]FDG PET/CT in multiple myeloma (MM) is currently the best technology to demonstrate patchy and extramedullary disease. However, [ …
Oct 1, 2022
Cite DOI
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
[177Lu]Lu-lilotomab satetraxetan, a novel CD37 directed radioimmunotherapy (RIT), has been investigated in a first-in-human phase 1/2a …
Oct 1, 2022
Cite DOI
Radionuclides for Targeted Therapy: Physical Properties
A search in PubMed revealed that 72 radionuclides have been considered for molecular or functional targeted radionuclide therapy. As …
Aug 25, 2022
Cite DOI